A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT07196722
- Phase
- Phase 2 / Phase 3
- Recruitment
- Enrolling participants
- Sponsor
- Janssen Research & Development, LLC
- Design
- Randomized
- Comparator
- Induction Study 1: Icotrokinra Dose 1; Induction Study 1: Icotrokinra Dose 2; Induction Study 1: Placebo; Induction Study 2: Icotrokinra; Induction Study 2: Placebo; Maintenance Study: Icotrokinra Dose 1; Maintenance Study: Icotrokinra Dose 2; Maintenance Study: Placebo
- Planned enrollment
- 1092
- Endpoint
- Induction Study 1: Number of Participants with Clinical Response at Week 12; Induction Study 2: Number of Participants with Clinical Remission at Week 12 (Co-Primary Endpoint); Induction Study 2: Number of Participants with Endoscopic Response at Week 12 (Co-Primary Endpoint); Maintenance Study: Number of Participants with Clinical Remission at Week 40 (Co-Primary Endpoint); Maintenance Study: Number of Participants with Endoscopic Response at Week 40 (Co-Primary Endpoint)
Study ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Portugal, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States.
Sites marked recruiting: Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Portugal, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Sep 19, 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1